{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:34:51Z","timestamp":1767890091735,"version":"3.49.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.canlet.2019.11.040","type":"journal-article","created":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T02:55:53Z","timestamp":1576032953000},"page":"132-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia"],"prefix":"10.1016","volume":"472","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1456-9997","authenticated-orcid":false,"given":"Pranav","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guan-Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Barbuti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishant","family":"Karadkhelkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingxuan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabesan","family":"Yoganathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Hua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2019.11.040_bib1","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.canlet.2019.11.040_bib2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/ardp.19963290707","article-title":"Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC)","volume":"329","author":"Zimmermann","year":"1996","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.canlet.2019.11.040_bib3","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2019.11.040_bib4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2014.03.003","article-title":"Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia","volume":"11","author":"Balabanov","year":"2014","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.canlet.2019.11.040_bib5","doi-asserted-by":"crossref","first-page":"10407","DOI":"10.18632\/oncotarget.2090","article-title":"Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFR\u03b1-expressing cells","volume":"5","author":"Shen","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.11.040_bib6","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4161\/cbt.28931","article-title":"SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells","volume":"15","author":"Bu","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.canlet.2019.11.040_bib7","first-page":"7149","article-title":"Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571)","volume":"62","author":"La Rosee","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.11.040_bib8","doi-asserted-by":"crossref","first-page":"25694","DOI":"10.1038\/srep25694","article-title":"Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2019.11.040_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/jcb.25975","article-title":"GSK1904529A, a potent IGF-IR inhibitor, reverses MRP1-mediated multidrug resistance","author":"Gupta","year":"2017","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.canlet.2019.11.040_bib10","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1159\/000487578","article-title":"Voruciclib, a potent CDK4\/6 inhibitor, antagonizes ABCB1 and ABCG2-mediated multi-drug resistance in cancer cells","volume":"45","author":"Gupta","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.canlet.2019.11.040_bib11","doi-asserted-by":"crossref","first-page":"39276","DOI":"10.18632\/oncotarget.5747","article-title":"A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo","volume":"6","author":"Anreddy","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.11.040_bib12","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.canlet.2016.09.025","article-title":"PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia","volume":"383","author":"Gupta","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2019.11.040_bib13","first-page":"2053","article-title":"Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor","volume":"6","author":"Ciardiello","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.11.040_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2016.06.008","article-title":"Quantifying ROS levels using CM-H","volume":"109","author":"Oparka","year":"2016","journal-title":"Methods"},{"key":"10.1016\/j.canlet.2019.11.040_bib15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1080\/10715760802317663","article-title":"Glutathione and apoptosis","volume":"42","author":"Circu","year":"2008","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.canlet.2019.11.040_bib16","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s13277-014-2644-z","article-title":"Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation","volume":"36","author":"Shi","year":"2015","journal-title":"Tumour Biol"},{"key":"10.1016\/j.canlet.2019.11.040_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1747-0285.2007.00556.x","article-title":"Crystal structure of the T315I mutant of AbI kinase","volume":"70","author":"Zhou","year":"2007","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.canlet.2019.11.040_bib18","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.18632\/oncotarget.2837","article-title":"HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation","volume":"6","author":"Kim","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.11.040_bib19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.canlet.2018.02.040","article-title":"Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: in vitro and in vivo","volume":"424","author":"Zhang","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2019.11.040_bib20","doi-asserted-by":"crossref","first-page":"7905","DOI":"10.1158\/0008-5472.CAN-08-0499","article-title":"Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2","volume":"68","author":"Dai","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.11.040_bib21","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.18632\/oncotarget.6711","article-title":"Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of doxorubicin","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.11.040_bib22","doi-asserted-by":"crossref","first-page":"10697","DOI":"10.18632\/oncotarget.4037","article-title":"EMT, CTCs and CSCs in tumor relapse and drug-resistance","volume":"6","author":"Mitra","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.11.040_bib23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/cyto.a.22613","article-title":"Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(\u00ae) CTC test","volume":"87","author":"Adams","year":"2015","journal-title":"Cytometry"},{"key":"10.1016\/j.canlet.2019.11.040_bib24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-981-13-0502-3_5","article-title":"Circulating tumor cells: the importance of single cell analysis","volume":"1068","author":"Heymann","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.canlet.2019.11.040_bib25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.vascn.2012.10.002","article-title":"Development of a high-throughput electrophysiological assay for the human ether-\u00e0-go-go related potassium channel hERG","volume":"67","author":"Gillie","year":"2013","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.canlet.2019.11.040_bib26","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1021\/acs.analchem.8b00725","article-title":"In situ visualization of hERG potassium channel via dual signal amplification","volume":"90","author":"Yang","year":"2018","journal-title":"Anal. Chem."},{"key":"10.1016\/j.canlet.2019.11.040_bib27","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1159\/000488169","article-title":"Molecular insights into hERG potassium channel blockade by Lubeluzole","volume":"45","author":"Gualdani","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.canlet.2019.11.040_bib28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/adt.2008.137","article-title":"Development of the predictor HERG fluorescence polarization assay using a membrane protein enrichment approach","volume":"6","author":"Piper","year":"2008","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.canlet.2019.11.040_bib29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.canlet.2017.03.011","article-title":"Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: in vitro and in vivo study","volume":"396","author":"Wang","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2019.11.040_bib30","doi-asserted-by":"crossref","first-page":"29760","DOI":"10.18632\/oncotarget.15964","article-title":"Effect of Y6, an epigallocatechin gallate derivative, on reversing doxorubicin drug resistance in human hepatocellular carcinoma cells","volume":"8","author":"Wen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.11.040_bib31","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3892\/mmr.2014.2167","article-title":"Phenethyl isothiocyanate inhibits growth of human chronic myeloid leukemia K562 cells via reactive oxygen species generation and caspases","volume":"10","author":"Wang","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.canlet.2019.11.040_bib32","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.18632\/oncotarget.806","article-title":"STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia","volume":"3","author":"Warsch","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.11.040_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073672","article-title":"Synergistic apoptosis of CML cells by buthionine sulfoximine and hydroxychavicol correlates with activation of AIF and GSH-ROS-JNK-ERK-iNOS pathway","volume":"8","author":"Chowdhury","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2019.11.040_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107210","article-title":"Pronounced effects of HERG-blockers E-4031 and erythromycin on APD, spatial APD dispersion and triangulation in transgenic long-QT type 1 rabbits","volume":"9","author":"Ziupa","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2019.11.040_bib35","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.canlet.2014.03.012","article-title":"HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia","volume":"348","author":"Yun","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2019.11.040_bib36","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.11.040_bib37","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.11.040_bib38","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrd2324","article-title":"Flying under the radar: the new wave of BCR-ABL inhibitors","volume":"6","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2019.11.040_bib39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/344251a0","article-title":"Acute leukaemia in bcr\/abl transgenic mice","volume":"344","author":"Heisterkamp","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2019.11.040_bib40","first-page":"1398","article-title":"Crkl enhances leukemogenesis in BCR\/ABL P190 transgenic mice","volume":"61","author":"Hemmeryckx","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.11.040_bib41","first-page":"1450","article-title":"Bafetinib, a dual Bcr-Abl\/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia","volume":"11","author":"Santos","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.canlet.2019.11.040_bib42","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature14119","article-title":"Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation","volume":"519","author":"Pemovska","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2019.11.040_bib43","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1158\/1535-7163.MCT-07-0444","article-title":"PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer","volume":"6","author":"Carpinelli","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2019.11.040_bib44","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0300-483X(02)00460-2","article-title":"Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis","volume":"181\u2013182","author":"Pietenpol","year":"2002","journal-title":"Toxicology"},{"key":"10.1016\/j.canlet.2019.11.040_bib45","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-1-4939-0888-2_2","article-title":"Cell cycle regulation by checkpoints","volume":"1170","author":"Barnum","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.canlet.2019.11.040_bib46","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature08675","article-title":"Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors","volume":"463","author":"Zhang","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2019.11.040_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2014.11.002","article-title":"The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade","volume":"18","author":"Kathawala","year":"2015","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.canlet.2019.11.040_bib48","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1002\/jcb.25975","article-title":"GSK1904529A, a potent IGF-IR inhibitor, reverses MRP1-mediated multidrug resistance","volume":"118","author":"Gupta","year":"2017","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.canlet.2019.11.040_bib49","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.4103\/0366-6999.235105","article-title":"Potential clinical risk of inflammation and toxicity from rare-earth nanoparticles in mice","volume":"131","author":"Chen","year":"2018","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.canlet.2019.11.040_bib50","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s00280-013-2160-7","article-title":"Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies","volume":"71","author":"Sonnichsen","year":"2013","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383519306068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383519306068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:46:47Z","timestamp":1759592807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383519306068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":50,"alternative-id":["S0304383519306068"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2019.11.040","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2019.11.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}